MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
A phase 1 clinical trial for IMA401, a bispecific T cell engager, showed manageable safety profiles in patients with advanced solid tumors. The study established a recommended phase 2 dose and observed antitumor activity, though some patients experienced dose-limiting toxicities.
Why it matters
This trial represents a potential advancement in immunotherapy for treating recurrent or refractory solid tumors, which are often difficult to address with standard treatments.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial | Nature Medicine
The content is a technical summary of a medical trial published in a scientific journal, using objective, clinical language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in